Aclaris Therapeutics, Inc. (ACRS)
How ACRS actually reacts to news — the realized, point-in-time move the market made, measured across 282 labeled events over the last three years with zero look-ahead.
ACRS’s median reaction, across the day.
Half of all Aclaris Therapeutics, Inc. news events land between -1.68% and +1.66% at 30 minutes.
Reaction stats as of 2026-08-13. Reaction = percent move vs. the price at the news timestamp.
Email me when ACRS moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to ACRS’s baseline. Nothing else.
Get “How ACRS reacts to news” as a PDF.
A free one-page summary: ACRS’s median reaction to news and the full breakdown by event type — the numbers on this page, in one page.
Recent ACRS events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Aclaris Therapeutics Receives Fast Track Designation for Modzatinib (ATI-2138) for Moderate to Severe Lichen Planus (LP) | Press release | GlobeNewswire | -0.33% | -2.80% | |
| Aclaris Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate and Clinical Update | Press release | GlobeNewswire | +0.24% | -3.94% | |
| Form 10-Q Aclaris Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -0.33% | -2.80% | |
| Form 8-K Aclaris Therapeutics, For: Aug 06 | SEC filing · Form 8-K | SEC EDGAR | +0.24% | -3.94% | |
| Form S-3ASR Aclaris Therapeutics, | SEC filing · Form S-3ASR | SEC EDGAR | -0.33% | -2.80% | |
| Form 8-K Aclaris Therapeutics, For: Jun 04 | SEC filing · Form 8-K | SEC EDGAR | +0.21% | -7.04% | |
| Aclaris Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference | Press release | GlobeNewswire | -0.22% | -0.65% | |
| Aclaris Therapeutics to Participate in the 2026 Bank of America Healthcare Conference | Press release | GlobeNewswire | +1.32% | +2.07% | |
| Aclaris Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate and Clinical Update | Press release | GlobeNewswire | -1.07% | +4.29% | |
| Form 10-Q Aclaris Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +1.32% | +2.07% | |
| Form 8-K Aclaris Therapeutics, For: May 07 | SEC filing · Form 8-K | SEC EDGAR | -1.07% | +4.29% | |
| Aclaris Therapeutics Announces Positive Full Top Line First-in-Human Results from Phase 1a Healthy Volunteer Clinical Trial of ATI-052, a Novel Potential First-in-Class Anti-TSLP/IL-4Ra Bispecific Antibody, and Announces Lichen Planus as Lead Indication f | Press release | GlobeNewswire | -0.48% | +0.48% | |
| Form 8-K Aclaris Therapeutics, For: Apr 28 | SEC filing · Form 8-K | SEC EDGAR | -0.48% | +0.48% | |
| Aclaris Therapeutics to Provide Clinical Update on Key Biologic and Oral Inhibitor Programs on April 28, 2026 | Press release | GlobeNewswire | -0.48% | +0.48% | |
| Form ARS Aclaris Therapeutics, For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +3.32% | +4.12% | |
| Form DEF 14A Aclaris Therapeutics, For: Jun 04 | SEC filing · Form DEF | SEC EDGAR | +3.32% | +4.12% | |
| Form DEFA14A Aclaris Therapeutics, | SEC filing · Form DEFA14A | SEC EDGAR | +3.32% | +4.12% | |
| Aclaris Therapeutics to Participate in the H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference | Press release | GlobeNewswire | -1.27% | +0.00% | |
| Results Presented at 2026 American Academy of Dermatology (AAD) Annual Meeting Provide Additional Support for the Therapeutic Potential of ATI-2138 | Press release | GlobeNewswire | +0.28% | +0.43% | |
| Aclaris Therapeutics Announces Poster on Results from Phase 2a Trial of ATI-2138 at the 2026 American Academy of Dermatology (AAD) Annual Meeting | Press release | GlobeNewswire | -0.28% | +2.22% | |
| Aclaris Therapeutics Completes Enrollment in Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis | Press release | GlobeNewswire | -1.29% | -5.18% | |
| Form 8-K Aclaris Therapeutics, For: Mar 10 | SEC filing · Form 8-K | SEC EDGAR | -0.14% | -0.57% | |
| Form 8-K Aclaris Therapeutics, For: Mar 09 | SEC filing · Form 8-K | SEC EDGAR | +1.75% | +7.31% | |
| Aclaris Therapeutics to Participate in the Leerink Partners 2026 Global Healthcare Conference | Press release | GlobeNewswire | -0.67% | +1.67% | |
| Aclaris Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | -2.84% | -1.26% | |
| Form 10-K Aclaris Therapeutics, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.42% | -6.82% | |
| Form 8-K Aclaris Therapeutics, For: Feb 26 | SEC filing · Form 8-K | SEC EDGAR | -2.84% | -1.26% | |
| Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Patients with Asthma with its Novel Bispecific Anti-TSLP/IL-4Ra Antibody ATI-052 | Press release | GlobeNewswire | +1.53% | +2.75% | |
| Aclaris Therapeutics to Participate in Two February Healthcare Conferences | Press release | GlobeNewswire | -1.14% | +1.14% | |
| Aclaris Therapeutics’ Novel ITK/JAK3 Inhibitor ATI-2138 Demonstrates Rapid and Sustained Hair Regrowth in Validated Murine Model of Alopecia Areata (AA) | Press release | GlobeNewswire | +3.02% | +0.78% | |
| Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Atopic Dermatitis (AD) with Its Novel Bispecific Antibody ATI-052 | Press release | GlobeNewswire | -1.53% | +1.92% | |
| Form 8-K Aclaris Therapeutics, For: Jan 12 | SEC filing · Form 8-K | SEC EDGAR | -1.53% | +1.92% | |
| Aclaris Therapeutics Announces Positive Interim Results of Phase 1a Trial of Anti-TSLP/IL-4Ra Bispecific Antibody ATI-052 Supporting Expedited Clinical Development | Press release | GlobeNewswire | -1.09% | -3.99% | |
| Form 8-K Aclaris Therapeutics, For: Jan 06 | SEC filing · Form 8-K | SEC EDGAR | -1.09% | -3.99% | |
| Aclaris Therapeutics Added to the NASDAQ Biotechnology Index (NBI) | Press release | GlobeNewswire | -0.33% | -0.65% | |
| Aclaris Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference | Press release | GlobeNewswire | -2.17% | -1.09% | |
| Aclaris Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | -3.06% | -0.87% | |
| Form 10-Q Aclaris Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -2.19% | +2.65% | |
| Form 8-K Aclaris Therapeutics, For: Nov 06 | SEC filing · Form 8-K | SEC EDGAR | -3.06% | -0.87% | |
| Aclaris Therapeutics to Participate in Three November Healthcare Conferences | Press release | GlobeNewswire | -0.42% | -2.50% | |
| Form 8-K Aclaris Therapeutics, For: Oct 14 | SEC filing · Form 8-K | SEC EDGAR | -1.59% | -4.23% | |
| Aclaris Therapeutics to Host In-Person and Webcast R&D Day, “Patient Focused Innovation: Addressing Gaps in Immuno-Inflammatory Markets”, in New York on October 14, 2025 | Press release | GlobeNewswire | -0.52% | -1.04% | |
| Aclaris Therapeutics Announces Late-Breaking Abstract and Oral Presentation On ATI-2138 Phase 2a Results at the 2025 European Academy of Dermatology and Venereology (EADV) Congress | Press release | GlobeNewswire | +1.44% | +2.40% | |
| Aclaris Therapeutics to Participate in Two September Healthcare Conferences | Press release | GlobeNewswire | -0.55% | +0.55% | |
| Aclaris Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | -0.65% | +1.29% | |
| Form 10-Q Aclaris Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +1.27% | +3.82% | |
| Form 8-K Aclaris Therapeutics, For: Aug 07 | SEC filing · Form 8-K | SEC EDGAR | -0.65% | +1.29% | |
| Aclaris Therapeutics Announces Positive Top-Line Results from Open-Label Phase 2a Trial of ATI-2138, a Potent and Selective Investigational Inhibitor of ITK and JAK3; Trial Achieves Primary and Key Secondary Endpoints | Press release | GlobeNewswire | +8.70% | -4.97% | |
| Form 8-K Aclaris Therapeutics, For: Jul 29 | SEC filing · Form 8-K | SEC EDGAR | +8.70% | -4.97% | |
| Aclaris Therapeutics Announces Leadership Transition | Press release | GlobeNewswire | +0.65% | -2.33% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the ACRS section they belong to.
More of the dataset.
ACRS earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Aclaris Therapeutics, Inc.'s median reaction calculated?
Every labeled ACRS news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 282 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 48% of ACRS's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-08-13.
Does ACRS's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.